https://orcid.org/0000-0002-2684-5277
References
- Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis. N Engl J Med. 2017;377(21):2013–2023.
- Rowe SM, Daines C, Ringshausen FC, et al. Tezacaftor-ivacaftor in residual function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024–2035.
- Flume PA, Fischer Biner R, Downey DG, et al. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who ware homozygous or heterozygous for Phe508del (EXTEND): an open-label extension study. Lancet Respir Med. 2021;9(7):733–746.
- Rogers GB, Taylor SL, Hoffman LR, et al. The impact of CFTR modulator therapies on CF airway microbiology. J Cyst Fibros. 2020;19(3):359–364.
- Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the CFTR potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–184.
- Hisert KB, Heltshe SL, Pope C, et al. Restoring CFTR function reduces airway bacteria and inflammation in people with cystic fibrosis. Am J Respir Crit Care Med. 2017;195(12):1617–1628.
- Harris JK, Wagner BD, Zemanick ET, et al. Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation. Ann Am Thorac Soc. 2020;17(2):212–220.
- Neerincx AH, Whiteson K, Phan JL, et al. Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients. ERJ Open Res. 2021;7(2):00731–2020.
- Dagenais RVE, Su VC, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med. 2021;10(1):23.
- Cookson W, Moffatt M, Rapeport G, et al. A pandemic lesson for global lung diseases: exacerbations are preventable. Am J Respir Crit Care Med. 2022;205(11):1271–1280.